Wall Street Zen Upgrades Phreesia (NYSE:PHR) to Buy

Key Points

• Wall Street Zen upgraded Phreesia from hold to buy, adding to a mixed but generally constructive analyst backdrop. Overall, nine analysts rate the stock Buy, nine Hold, and one Sell, with a consensus rating of Hold.
• Phreesia reported a Q1 earnings beat, posting EPS of $0.05 versus the $0.02 estimate and revenue of $130.94 million above expectations. Revenue rose 12.9% year over year, and the stock was up 3.7% in recent trading.
• The company also issued FY2027 revenue guidance of $510 million to $520 million, which was roughly in line with market expectations. Meanwhile, insider sales and a pending securities class action add some headline risk, though they do not change the operating results.

Phreesia (NYSE:PHR - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

Other analysts have also issued research reports about the company. Needham & Company LLC decreased their price objective on Phreesia from $35.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. KeyCorp decreased their price objective on Phreesia from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Monday, April 13th. BMO Capital Markets decreased their price objective on Phreesia from $32.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday, March 31st. Piper Sandler lowered Phreesia from an "overweight" rating to a "neutral" rating and set a $12.00 price objective on the stock. in a report on Thursday. Finally, Canaccord Genuity Group decreased their price objective on Phreesia from $22.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $16.65.

Phreesia Stock Up 3.7%

Shares of PHR stock opened at $9.80 on Friday. The stock's 50 day simple moving average is $9.46 and its 200 day simple moving average is $13.57. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The company has a market capitalization of $605.28 million, a price-to-earnings ratio of 65.33 and a beta of 0.89.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Wednesday, May 27th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. The firm had revenue of $130.94 million for the quarter, compared to analyst estimates of $130.08 million. Phreesia had a return on equity of 5.30% and a net margin of 1.85%.The company's revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) EPS. As a group, research analysts predict that Phreesia will post 0.28 EPS for the current year.

Insider Buying and Selling

In related news, CFO Balaji Gandhi sold 3,829 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the completion of the transaction, the chief financial officer owned 146,740 shares in the company, valued at $1,652,292.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Yvonne Hui sold 10,063 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $9.08, for a total value of $91,372.04. Following the transaction, the insider owned 25,991 shares of the company's stock, valued at $235,998.28. This trade represents a 27.91% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 50,493 shares of company stock worth $461,983 over the last 90 days. Corporate insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently modified their holdings of PHR. Pale Fire Capital SE bought a new position in shares of Phreesia during the 1st quarter worth approximately $72,481,000. Granahan Investment Management LLC raised its position in Phreesia by 73.8% in the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company's stock valued at $40,601,000 after purchasing an additional 1,018,987 shares during the last quarter. Prosight Management LP bought a new position in Phreesia in the 4th quarter valued at $16,533,000. Millennium Management LLC raised its position in Phreesia by 730.7% in the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company's stock valued at $25,028,000 after purchasing an additional 936,033 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Phreesia in the 4th quarter valued at $15,213,000. Institutional investors own 92.10% of the company's stock.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia reported fiscal Q1 2027 results that beat Wall Street expectations, with EPS of $0.05 versus $0.02 expected and revenue of $130.94 million above estimates; the company also cited 12.9% year-over-year revenue growth, which is helping sentiment. Article Title
• Positive Sentiment: The company also issued FY2027 revenue guidance of $510 million to $520 million, which is roughly in line with consensus and suggests management sees continued growth ahead. Article Title
• Positive Sentiment: Analysts reacted favorably overall, with DA Davidson reaffirming a Buy rating and Piper Sandler still seeing upside even after a downgrade to Neutral. Article Title
• Neutral Sentiment: Several law firms are publicizing a pending securities class action and a July 13, 2026 lead-plaintiff deadline for investors who bought Phreesia shares during the class period. These notices add headline risk, but they are procedural updates rather than new company operating news. Article Title
• Neutral Sentiment: Market coverage also noted that Phreesia shares rose after the earnings and revenue beat, reinforcing that the stock’s move is being driven mainly by the stronger-than-expected quarterly results. Article Title

Phreesia Company Profile

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.